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ABSTRACT
Background: Elevated plasma homocysteine is a risk factor for
Alzheimer disease, but the relevance of homocysteine lowering to
slow the rate of cognitive aging is uncertain.
Objective: The aim was to assess the effects of treatment with B
vitamins compared with placebo, when administered for several
years, on composite domains of cognitive function, global cognitive
function, and cognitive aging.
Design: A meta-analysis was conducted by using data combined
from 11 large trials in 22,000 participants. Domain-based z scores
(for memory, speed, and executive function and a domain-composite
score for global cognitive function) were available before and after
treatment (mean duration: 2.3 y) in the 4 cognitive-domain trials
(1340 individuals); Mini-Mental State Examination (MMSE)–type
tests were available at the end of treatment (mean duration: 5 y) in
the 7 global cognition trials (20,431 individuals).
Results: The domain-composite and MMSE-type global cognitive
function z scores both decreased with age (mean6 SE:20.0546 0.004
and20.0366 0.001/y, respectively). Allocation to B vitamins lowered
homocysteine concentrations by 28% in the cognitive-domain trials
but had no significant effects on the z score differences from base-
line for individual domains or for global cognitive function (z score
difference: 0.00; 95% CI: 20.05, 0.06). Likewise, allocation to B
vitamins lowered homocysteine by 26% in the global cognition tri-
als but also had no significant effect on end-treatment MMSE-type
global cognitive function (z score difference:20.01; 95% CI: 20.03,
0.02). Overall, the effect of a 25% reduction in homocysteine equated
to 0.02 y (95% CI: 20.10, 0.13 y) of cognitive aging per year and
excluded reductions of .1 mo per year of treatment.
Conclusion: Homocysteine lowering by using B vitamins had no
significant effect on individual cognitive domains or global cog-
nitive function or on cognitive aging. Am J Clin Nutr 2014;100:
657–66.
INTRODUCTION
Cognitive function, and its component domains of memory,
speed, and executive function, decline gradually over the life span
in most people (1). The rate of decline in cognitive function with
increasing age is faster in some people, resulting in clinical syn-
dromes of “mild cognitive impairment” and dementia (including
Alzheimer disease) (1). With improvements in life expectancy,
the number of cases with mild cognitive impairment and dementia
is likely to increase worldwide. Observational studies have shown
that elevated plasma homocysteine is a potentially modifiable
risk factor for “cognitive aging” (2–6). The “homocysteine hy-
pothesis” of Alzheimer disease was suggested in response to
observations from retrospective studies that cases with clinically
diagnosed or histologically confirmed Alzheimer disease had
1 From the Clinical Trial Service Unit and Epidemiological Studies Unit,
University of Oxford, Oxford, United Kingdom (R Clarke, DB, SP, SL, JA,
JH, and R Collins); the Department of Human Nutrition, University of Ota-
go, Dunedin, New Zealand (MS); the Section for Pharmacology and De-
partment of Public Health and Primary Care, University of Bergen, Bergen,
Norway (SJPME); the Department of Epidemiology, School for Public
Health and Primary Care, CAPHRI, Maastricht University Medical Centre,
Maastricht, Netherlands (SJPME); the Section of Hematology and Coagula-
tion, Department of Internal Medicine, Institute of Medicine, Sahlgrenska
Academy at the University of Gothenburg, Gothenburg, Sweden (CL); the
Division of Cardiovascular and Medical Science, University of Glasgow,
Glasgow, United Kingdom (DJS); the School of Medicine and Pharmacol-
ogy, The University of Western Australia, Perth, Australia (GJH); the Pop-
ulation Health Research Institute and Department of Medicine, McMaster
University, Hamilton, Canada (EL); the Department of Neurology, Western
University, London, Canada (JDS); Unite´ de Recherche en Epide´miologie
Nutritonnelle (UREN), Sorbonne-Paris-Cite´, UMR Inserm U557, France
(PG); Inra U1125, Paris, France (PG); Cnam, Paris, France (PG); Universite´
Paris 13, CRNH IdF, Bobigny, France (PG); the Division of Human Nutrition
and Epidemiology, Wageningen University, Wageningen, Netherlands
(LCdG); the Department of Nutrition and Public Health Intervention Re-
search, London School of Hygiene and Tropical Medicine, London, United
Kingdom (ADD); and the Channing Division of Network Medicine, Depart-
ment of Medicine, Brigham and Women’s Hospital, Boston, MA (FG).
2 Investigators in the B-Vitamin Treatment Trialists’ Collaboration are
listed in Appendix A after the References.
3 RClarke, DB, and SP contributed equally to this article.
4 Supportedby the British Heart Foundation, the UK Medical Research Coun-
cil, Cancer Research UK, and the UK Food Standards Agency (N05072) and
Department of Health. Sources of funding for the individual trials are described in
their separate publications. The Clinical Trial Service Unit and Epidemiological
Studies Unit, where the B-Vitamin Treatment Trialists’ Collaboration Secretariat
is located, has a policy of not accepting fees, honoraria, or paid consultancies
directly or indirectly from industry. It receives funding from the British
Heart Foundation, UK Medical Research Council, and Cancer Research UK.
This is an open access article distributed under the CC-BY license (http://
creativecommons.org/licenses/by/3.0/).
5 Address correspondence to R Clarke, Clinical Trial Service Unit and
Epidemiological Studies Unit, Richard Doll Building, University of Oxford,
Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, United Kingdom.
E-mail: robert.clarke@ctsu.ox.ac.uk.
ReceivedSeptember 28, 2013. Accepted for publication May 8, 2014.
First published online June 25, 2014; doi: 10.3945/ajcn.113.076349.
Am J Clin Nutr 2014;100:657–66. Printed in USA. 657
higher homocysteine concentrations compared with age- and sex-
matched controls (2, 3). Subsequently, prospective studies in healthy
older people reported that individuals with homocysteine con-
centrations $14 mmol/L had a 2-fold higher risk of Alzheimer
disease after adjustment for known risk factors (5, 6). The results
of these studies (2, 4–6) prompted the design of several randomized
trials, testing whether dietary supplementation with folic acid and
vitamin B-12 to lower homocysteine concentrations could slow
the rate of age-related cognitive decline and thereby reduce the
risk of dementia, including Alzheimer disease.
A few trials, typically involving several hundred people,
assessed the effects of B vitamins administered for a few years on
domain-specific tests of cognitive function (ie, memory, speed,
and executive function and their sum, domain-composite score)
before and after treatment (7–10). Other trials, typically in-
volving several thousand individuals, assessed the effects of B
vitamins administered for w5 y on cardiovascular disease out-
comes (11–17) and included some assessments of global cog-
nitive function [typically assessed by using the Mini-Mental
State Examination (MMSE)6 (18) or the Telephone Interview for
Cognitive Status–Modified (TICS-M) (19–21)] at the end of the
treatment period.
The B-Vitamin Treatment Trialists’ Collaboration was established
to conduct meta-analyses of data from individual participants in
placebo-controlled trials assessing the effects of supplementation
with B vitamins on cardiovascular disease, cancer, and cognitive
function (22). The primary aims of the present meta-analysis were
to evaluate the effects of homocysteine lowering by B-vitamin
treatment on cognitive function and on the rate of cognitive aging.
Treatment effects were expressed both as B vitamins compared
with placebo differences and as differences by extent of homo-
cysteine lowering. When trial data permitted, effects on changes
in specific cognitive domains were assessed and effect modifi-
cation by a variety of factors (eg, age, sex, duration of treatment,
smoking, prior stroke or cognitive impairment, folic acid forti-
fication, and baseline plasma concentrations of folate, vitamin
B-12, and homocysteine) was also evaluated.
METHODS
Trial eligibility
Randomized trials were sought by 2 investigators (R Clarke
and DB) who searched electronic databases, including PubMed
(www.ncbi.nlm.nih.gov/pubmed) and PsychINFO (www.ebscohost.
com/academic/psycinfo), with the use of search terms “cognitive
function,” “cognitive impairment,” “cognitive decline,” “mem-
ory” and “memory impairment,” and “folic acid” or “B-vitamins”
or “homocysteine lowering therapy” for reports in the English
language (Supplemental Figure 1 under “Supplemental data” in
the online issue). Unpublished trials were sought through electronic
searches, hand-searching reference lists of relevant reports and
discussions with experts in the field. Nine of ten randomized trials
assessing the effects on cognitive function of supplementation
with B vitamins containing folic acid met the following criteria:
1) duration of .3 mo, 2) .100 participants unselected for
cognition-related diseases other than heart attack or stroke/transient
ischemic attack (TIA), 3) homocysteine-lowering treatment only,
and 4) availability of sufficient data by September 2010. The
Folic Acid and Carotid Intima-Media Thickness (FACIT) trial
declined to contribute individual participant data, but the
published results were sufficiently detailed to allow the trial’s
inclusion (10).
Baseline and follow-up data
For each randomly assigned participant, information was sought
on characteristics recorded before randomization, the randomly
allocated treatment, the dates of randomization and follow-up
visits (or time from randomization), and results of any measure of
cognitive function before, during, and at the end of the scheduled
treatment period. The individual participant data were checked
for consistency with any published reports, and investigators
were also asked to confirm summary data by allocated treatment
to help ensure that the data were incorporated correctly into the
meta-analysis.
Measures of cognitive function
Four trials (7–10) assessed effects of B-vitamin treatment on
specific cognitive domains, and 7 assessed effects of B-vitamin
treatment on MMSE-type global cognitive function scores (Table 1
and Supplemental Table 1 under “Supplemental data” in the online
issue). Each of the 4 “cognitive-domain trials” used multiple domain-
specific tests that were combined by a standard approach to yield
composite scores for memory, speed, executive function, and global
cognitive function (Table 1 and Supplemental Table 1 and Sup-
plemental Methods under “Supplemental data” in the online
issue). Each of the 7 “global cognition trials” (11–17) typically used
a single test of global cognitive function: the MMSE, the Telephone
Interview for Cognitive Status (TICS), or the TICS-M.
The MMSE is a brief test of cognitive function involving 5
sections (orientation, immediate and delayed recall, attention and
calculation, language, and visuospatial abilities). The TICS and
TICS-M are telephone adaptations of the MMSE. The 13-item
TICS-M includes 4 sections (orientation; recent and delayed recall;
attention and calculation; semantic memory, comprehension, and
language). The MMSE-type cognitive function tests typically
provide a single score, but for the Study of the Effectiveness of
Additional Reductions in Cholesterol and Homocysteine (SEARCH)
trial (17) the 4 components of the TICS-M test were also available,
permitting additional assessments of individual domains. (Note
that terminology, and in particular the use of the term “global,”
has varied in previous reports, but because both types of test
cover multiple domains the overall score from both types of test
is termed a “global cognitive score” in this article.)
Statistical analyses
Homocysteine reductions were estimated from regression of
follow-up blood homocysteine concentrations (in the blood
samples taken nearest the midpoint of the trial when multiple
replicate samples were available) on allocated treatment after
adjustment for baseline homocysteine concentration. To test the
hypothesis that homocysteine lowering attenuates the annual rate
6Abbreviations used: FACIT, Folic Acid and Carotid Intima-Media Thick-
ness; MMSE, Mini-Mental State Examination; SEARCH, Study of the Ef-
fectiveness of Additional Reductions in Cholesterol and Homocysteine; TIA,
transient ischemic attack; TICS, Telephone Interview for Cognitive Status;
TICS-M, Telephone Interview for Cognitive Status–Modified.
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of cognitive aging pro rata to the percentage of homocysteine
reduction and duration of reduction, the equivalent study years at
a 25% homocysteine reduction for each trial were estimated by di-
viding the trial-specific percentage of homocysteine reduction by 25
and multiplying by the mean duration of treatment in that trial (23).
Because the cognitive tests and populations studied differed,
scores from each trial were rescaled, as follows: first the residual
SDs of the end-treatment domain-specific scores, the domain-
composite global cognitive function scores, and the MMSE-type
global cognitive function scores were estimated after adjustment
for end-treatment age (as a continuous variable by using linear
regression analysis); then, the before- and after-treatment scores
were each scaled by dividing by the estimated residual SD (Sup-
plemental Table 2 under “Supplemental data” in the online issue).
Standard linear models and Pearson correlation coefficients
were used to compute all statistics on the z scores. Self-correlations
were calculated as the Pearson correlation in participants with
global cognitive z scores measured at baseline and at end of
treatment. Preliminary analyses compared the properties of domain-
composite and MMSE-type global cognitive function scores and the
effects of age and prior stroke or TIA on the z scores.
For the main comparisons, end-treatment MMSE-type global
cognitive function scores were adjusted for age to remove some
between-person variation, whereas this was not relevant to
comparisons of changes in z scores in the trials. All com-
parisons were conducted separately within each trial and the
trial-specific estimates subsequently combined by using inverse-
variance–weighted averaging.
The z score differences per year at a 25% homocysteine re-
duction were estimated by dividing the study z score difference
by the trial equivalent years at a 25% homocysteine reduction.
These estimates were then divided by the effect of age on the
respective global cognitive function score (domain-composite or
MMSE-type) estimated over all trials with that score (to provide
equivalent years of cognitive aging). Additional details of how
the summary results from the FACIT trial were incorporated are
provided in the Supplementary Material: Methods Appendix
(under “Supplemental data” in the online issue). All analyses
used SAS version 9.2 (SAS Institute).
RESULTS
Characteristics of the participating trials
The 4 cognitive-domain trials reported results for domain-specific
and domain-composite global cognitive function scores in 1423
individuals, of whom 1340 (94%) had complete cognitive data at the
end of the scheduled treatment period (Table 1 and Supplemental
Table 1 under “Supplemental data” in the online issue). The 7 global
cognition trials reported MMSE-type scores in 20,431 participants
at end of treatment (with 7199 of these individuals also having
MMSE-type scores recorded before starting treatment). The mean
duration of treatment varied from 0.3 to 3.0 y (overall mean: 2.3 y)
in the 4 cognitive-domain trials and from 1.0 to 7.1 y (overall mean:
5.0 y) in the global cognition trials. All trials compared the effects
of folic acid with placebo, except for one trial (13) that used
5-methyltetrahydrofolate. The daily doses of folic acid ranged from
0.4 to 2.5 mg (Supplemental Table 3 under “Supplemental data”
in the online issue). All but one trial (10) also added vitamin
B-12 (dose range: 0.02–1 mg). The mean (6SD) age at entry was
68 6 5 y in the cognitive-domain trials and 66 6 6 y in the global
cognition trials (Table 1).
Effects on plasma homocysteine concentrations
Allocation to B vitamins was associated with a 28.4% and 26.1%
reduction in plasma concentrations of homocysteine in the cognitive-
domain trials and global cognition trials, respectively (Table 1).
Allocation to B vitamins was associated with an approximate 3- to
5-fold increase in median plasma folate concentrations (Supple-
mental Table 4 under “Supplemental data” in the online issue) and
a 2-fold increase in median vitamin B-12 concentrations in all
trials, which showed a high level of compliance with the allo-
cated treatment (Supplemental Table 5 under “Supplemental data” in
the online issue).
TABLE 2
Correlations and variance of global cognitive function scores in placebo-allocated participants with repeat assessments1
Trial (ref) Duration
Global cognitive function score
Domain-composite MMSE-type Correlation between
domain-composite
and MMSE-type scoreSelf-correlation VE VC VC:VE ratio Self-correlation VE VC VC:VE ratio
y
Cognitive-domain trials
Lewerin (8) 0.3 0.92 1.00 0.16 0.16
Eussen (7) 0.5 0.90 1.00 0.43 0.43 0.75 1.00 0.48 0.48 0.63
McMahon (9) 2.2 0.86 1.00 0.27 0.27 0.40 1.00 1.29 1.29 0.49
FACIT (10)2 3.0 1.00 0.23 0.23
Global cognition trials
Stott (11) 1.0 0.76 1.00 0.50 0.50
VISP (15) 1.8 0.54 1.00 0.87 0.87
HOPE-2 (12) 4.8 0.53 1.00 0.92 0.92
WAFACS (14)3 6.0 0.41 1.00 1.13 1.13
1 FACIT, Folic Acid and Carotid Intima-Media Thickness; HOPE-2, Heart Outcomes Prevention Evaluation-2; MMSE, Mini-Mental State Examination;
ref, reference; VC, variance of change in z score from baseline to end of treatment; VE, variance of end-treatment z score (adjusted for age); VISP, Vitamin
Intervention for Stroke Prevention; WAFACS, Women’s Antioxidant and Folic Acid Cardiovascular Study.
2 Published data only.
3WAFACS also measured cognitive function at 2 and 4 y after the initial measurement, and the self-correlations over these intervals were 0.47 and 0.43.
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Characteristics of the instruments used to assess cognitive
function
The correlations and variances of global cognitive func-
tion scores in placebo-allocated participants with before- and
after-treatment (ie, repeat) assessments, with the trials ordered by
duration of treatment within the trial categories, are shown in
Table 2. The correlation between baseline and end-treatment
scores was very high (0.92–0.86) for the domain-composite score,
but trials with this information had a limited duration of treatment
(range: 0.3–2.2 y). Correspondingly, the change in score over
a trial had a substantially lower variance than that of a single-
score measurement adjusted for age, with the ratios of variances
ranging from 0.16 to 0.38 in studies with treatment durations of
up to 3 y [including published results from FACIT (10)].
Two of the cognitive-domain trials also measured an MMSE-
type cognitive test; and in each trial, the self-correlation of the
MMSE-type scores (0.40 and 0.75) was lower than the self-
correlation of the domain-composite score. In the trials with
durations of w2 y or more, the variance of the change in the
MMSE-type score was very similar to the variance of a single
age-adjusted score at the end of the trial. Domain-composite and
MMSE-type global cognitive function scores were moderately
correlated with each other in the 2 trials that assessed this (0.49
and 0.63).
Effects of age on cognitive function
The relation of the global cognitive function scores with age
and history of stroke or TIA is shown in Table 3. Among in-
dividuals selected for entry into these trials, the proportion of
variance explained by age in the different trials was fairly low
(varying from 2% to 13% for the MMSE-type test). In trials that
did not primarily recruit participants with prior stroke/TIA, both
the domain-composite and MMSE-type global cognitive func-
tion scores declined significantly with age, but the relation was
50% stronger with the domain-composite score (mean 6 SE:
20.0546 0.004 compared with 20.0366 0.001/y). The effects
in the individual trials were consistent with the overall estimates,
except for a weaker effect seen in the Heart Outcomes Prevention
Evaluation-2 trial (12) (Table 3). After adjustment for age, history
of stroke/TIAwas associated with a 20.135 6 0.027 lower score
(ie, equivalent tow4 y of aging) in all trials in participants with
a prior history of stroke or TIA, but the proportion of variance
explained by history of stroke/TIA was also low (0–3%) due to
the low prevalence of stroke at baseline.
Effects of B vitamins on domain-specific scores
The effect of B vitamins on specific domains of cognitive
function and on the domain-composite global cognitive function
score using change from baseline in the cognitive-domain trials is
shown in Figure 1. Overall, allocation to B vitamins had no sig-
nificant effect on the changes in the domain-specific scores for
memory [z score difference: 0.02 (95% CI: 20.06, 0.10); speed:
0.03 (95% CI: 20.02, 0.08); executive function: 20.05 (95%
CI: 20.14, 0.03)] or the domain-composite score (0.00; 95%
CI:20.05, 0.06). Neither were there any significant effects of
B vitamins on the memory or executive function domains of cog-
nitive function when the data from the cognitive-domain trials
were combined with additional data from the Women’s Anti-
oxidant and Folic Acid Cardiovascular Study (14) and SEARCH
(17) trials that had such data (Supplemental Figure 2 under
“Supplemental data” in the online issue). Among the cognitive-
domain trials, there was significant heterogeneity between the
trials for the effects of B vitamins on memory (x23 = 11.3,
P = 0.01), speed (x23 = 12.3, P = 0.006), and domain-composite
global cognitive function (x23 = 13.6, P = 0.004) but not for
executive function (x23 = 1.4, P = 0.71), with the heterogeneity
being chiefly attributable to the FACIT trial.
Effects of B vitamins on MMSE-type scores
The effect of B vitamins onMMSE-type global cognitive function
scores at the end of the treatment period in the global cognition
trials is shown in Figure 2. Compared with the placebo control,
allocation to B vitamins had no significant effect on MMSE-type
score in the 20,431 individuals with data on cognitive function
FIGURE 1. Effects of B vitamins on specific domains of cognitive function and on a domain-composite score by using change from baseline in the
cognitive-domain trials. The z scores for individual trials and the total for the cognitive-domain trials are shown separately for memory, speed, and executive
function and for a domain-composite global cognitive function score. Black squares represent z score differences for the individual trials and the horizontal
lines represent 95% CIs. The size of the squares is inversely proportional to the variance. Diamonds represent the z scores and 95% CIs for all trials.
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(z score difference: 20.01; 95% CI: 20.03, 0.02), nor was there
any effect of B vitamins on MMSE-type global cognitive function
in the cognitive-domain trials (Supplemental Figure 3 under “Sup-
plemental data” in the online issue). Moreover, there was no sig-
nificant effect of B vitamins on MMSE-type score in any of the
subgroups considered, including age at randomization (albeit
only one-third were aged .70 y), sex, smoking status, history of
stroke, folic acid fortification, duration of treatment, and by approx-
imate thirds of pretreatment concentrations of folate, vitamin
B-12, and homocysteine or by presence or absence of cognitive
impairment at baseline (Supplemental Figure 4 under “Supple-
mental data” in the online issue). (Individuals were defined as
having cognitive impairment at baseline if they had an MMSE
score ,24 or a TICS score ,31 or a TICS-M score ,22). In
particular, there was no heterogeneity in the effect of treatment
on score even among individuals with folate concentrations
,10 nmol/L, with vitamin B-12 concentrations ,250 pmol/L, or
with homocysteine concentrations $15 mmol/L compared with
those with normal plasma concentrations of these markers of
B-vitamin status (Supplemental Figure 4 under “Supplemental
data” in the online issue).
Information on the effect of B vitamins on global cognitive function
from the 4 trials with the use of change in the domain-composite
score and the 7 trials that used end-treatment MMSE-type scores
is shown in Figure 3. The score differences by allocated treat-
ment with B vitamins were also expressed as differences per year
at a 25% homocysteine reduction and, by using the score type–
specific relations with age provided in Table 3, as years of cog-
nitive aging equivalent. The overall estimates of the effect of
B vitamins on global cognitive function were not significant
when combined by any of these approaches (Figure 3 and Sup-
plemental Figure 5 under “Supplemental data” in the online issue).
The weighted average effect per year of a 25% homocysteine
reduction with B vitamins was 0.02 y (95% CI: 20.10, 0.13 y)
of cognitive aging (Figure 3) and there was no significant het-
erogeneity in this effect between studies (x210 = 14.3, P = 0.2).
DISCUSSION
The present meta-analysis in 22,000 participants from 11 ran-
domized trials has shown that homocysteine lowering by dietary
supplementation with B vitamins for w5 y does not have an
impact on cognitive aging in older people with or without vas-
cular disease. Allocation to B vitamins had no material effect on
domain-specific and domain-composite scores in the 4 cognitive
trials or on end-treatment MMSE-type cognitive scores in 7 global
cognition trials, and there was no evidence of effect modification
by pretreatment concentrations of folate, vitamin B-12, and ho-
mocysteine. With access to individual results on 20,000 partic-
ipants (together with the availability of sufficient detail in the
published report from FACIT), the present report was based on
an additional 60,000 equivalent person-years at a 25% homo-
cysteine reduction than the previous meta-analysis (10) and
permitted a combined analysis of data from all available trials that
used cognitive aging. Overall, in all trials combined, the weighted
average effect of a 25% homocysteine reduction equated to 0.02 y
(95% CI:20.10, 0.13 y) of cognitive aging per year, with the lower
CI excluding an effect greater than w1 mo less aging.
In contrast with previous meta-analyses that addressed the
effects of B vitamins on cognitive function or dementia (24, 25),
the present meta-analysis took account of differences in the duration
of treatment and extent of homocysteine reduction when assessing
the effects of B vitamins on cognitive aging. The approach adopted
for the analyses of cognitive aging used all of the available
randomized evidence for the effects of B vitamins on cognitive
function, after appropriate weighting for differences between
trials by duration of treatment and extent of homocysteine re-
duction. The analyses for global cognitive function showed no
significant heterogeneity between the effects on cognitive aging
in the 11 different trials (Figure 3), although some heterogeneity
was seen in the findings for the cognitive-domain trials, which
was mainly attributable to the FACIT trial (Figure 1).
The instruments used to assess cognitive function differed
between trials, which could have contributed heterogeneity. Memory
contributed approximately one-third of the weight in domain-
composite scores and only approximately one-fifth of the weight
in MMSE scores but approximately half of the weight in TICS-M
scores (21). In addition, the domain-composite global cognitive
score from FACIT included a higher proportion of tests of speed
FIGURE 2. Effects of B vitamins on MMSE-type global cognitive func-
tion score at the end of the treatment period in the global cognition trials.
The z score for differences and their 95% CIs for MMSE-type global cog-
nitive function scores are shown for individual trials and as the total for all
trials. The z score differences are for B-vitamins compared with placebo.
* refers to B-vitamin based treatment vs placebo. HOPE-2, Heart Outcomes
Prevention Evaluation-2; MMSE, Mini-Mental State Examination; SEARCH,
Study of the Effectiveness of Additional Reductions in Cholesterol and
Homocysteine; SU.FOL.OM3, Supplementation with Folate, vitamin B6
and B12 and/or Omega-3 fatty acids; VISP, Vitamin Intervention for Stroke
Prevention; VITATOPS, Vitamins to Prevent Stroke; WAFACS, Women’s
Antioxidant and Folic Acid Cardiovascular Study.
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and evaluated more domains of speed (eg, sensorimotor, com-
plex, and information processing speed) than in any other trial.
Thus, the possibility that homocysteine lowering benefits solely
these specific domains cannot be excluded. However, overall in the
present meta-analysis, allocation to B vitamins had no significant
effect on any of the individual domains of global cognitive
function that could be assessed. Advances in functional neuro-
imaging may identify indicators of various aspects of cognitive
aging and help provide more objective assessments of cognitive
function (and calibration of instruments) for future studies.
The FACIT trial examined the effects of lowering homo-
cysteine concentrations with a low dose of folic acid of 0.8 mg
daily on 5 different cognitive domains and reported significant
effects on the 3-y change in memory equivalent to cognitive
performance of someone that is 4.7 y (95% CI: 1.1, 8.3 y)
younger in age in 818 healthy participants with homocysteine
concentrations$13 mmol/L (10). On average, participants in the
FACIT trial were younger (60 compared with 66 y) and had
lower mean plasma folate concentrations (12 compared with 15
nmol/L) than those in all of the global cognition trials. However,
the present study found no effect of supplementation on MMSE-
type scores in subgroups with lower folate concentrations or at
younger ages (Supplemental Figure 3 under “Supplemental data”
in the online issue). In addition, the participants in the FACIT
trial were individuals with elevated homocysteine concentrations
and normal serum vitamin B-12 concentrations ($200 pmol/L),
but the present meta-analysis found no heterogeneity in the ef-
fects of supplementation among those with vitamin B-12 con-
centrations ,250 pmol/L compared with those with higher plasma
vitamin B-12 concentrations (Supplemental Figure 4 under
“Supplemental data” in the online issue). Although it is possible
that the results of the FACIT trial may reflect some special at-
tributes of the FACIT trial population or design (eg, correction
of folate deficiency in individuals after excluding those with
vitamin B-12 deficiency), the present meta-analysis does not provide
any support for such an interpretation. Hence, in the absence of
any consistent effects in different subgroups or over different
cognitive domains, the differences between the results in FACIT
and the other trials may be due to chance.
Consistent with previous reports (26, 27), the present study
showed that, for the domain-composite score, change in z score
offered some advantage over end-treatment z scores. The ratios of
the variances of these 2 measures were 1:6 to 1:3, and hence (be-
cause power is a function of the variance of an individual obser-
vation divided by the number of observations) the use of change in
domain-composite score equates to having 3–6 times as many in-
dividuals compared with the use of the end-treatment domain-
composite score. However, for the MMSE-type scores, the variances
of the change in score and end-treatment score were similar and so
little would be gained by using change in MMSE-type z score.
Both domain-composite and MMSE-type scores showed
strong inverse associations with age, but the relation wasw50%
steeper for the domain-composite score, suggesting that this was
a somewhat more sensitive measure. However, offsetting these
advantages of the change in domain-composite score were the
longer durations and greater study sizes that were feasible in trials
carrying out end-treatment MMSE-type assessments. An ex-
amination of the SEs of the estimates in Figure 3 indicates
how the global cognitive measure, number of participants and
duration of treatment influenced the relative contributions from
FIGURE 3. Effects of B vitamins on cognitive aging in all available trials per year at a 25% reduction in homocysteine. The z score differences and their
95% CIs are provided for the domain-composite global cognitive function score in each cognitive-domain trial and for the MMSE-type global cognitive
function score in the other trials. The years of cognitive aging equivalent and their 95% CIs are also provided for individual trials and their totals. The years of
cognitive aging equivalent were determined on the basis of a 0.054/y reduction in the cognitive domain trial score and a 0.036/y reduction in the global
cognition trial score. * indicates that the age association was based on 0.054 per year reduction in domain-composite z score for cognitive-domain trials and on
0.036 per year reduction in MMSE-type cognitive z score. FACIT, Folic Acid and Carotid Intima-Media Thickness; HOPE-2, Heart Outcomes Prevention
Evaluation-2; MMSE, Mini-Mental State Examination; SEARCH, Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine; SU.
FOL.OM3, Supplementation with Folate, vitamin B6 and B12 and/or Omega-3 fatty acids; tHcy, total homocysteine; VISP, Vitamin Intervention for Stroke
Prevention; VITATOPS, Vitamins to Prevent Stroke; WAFACS, Women’s Antioxidant and Folic Acid Cardiovascular Study.
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individual trials. The FACIT trial (10), the largest of the
cognitive-domain trials with 818 participants, contributed 2454
equivalent person-years, whereas SEARCH, the largest of the
global cognition trials with 8891 participants (17), contributed
63,439 equivalent person-years. In FACIT, the SE of the effect
of treatment was 0.034, whereas in SEARCH the SE was 0.021.
Thus, the SE of SEARCH was approximately two-thirds that for
FACIT, showing how a larger number of participants can offset
a less stringent measure of global cognitive function. Moreover,
for comparisons of the effect of treatment on global cognitive
function per year at a 25% homocysteine reduction, the SE of the
SEARCH result was only one-fifth of that for FACIT, showing the
additional relevance of longer duration of treatment (Supplemental
Figure 2 under “Supplemental data” in the online issue).
Trials in persons selected on the basis of a prior diagnosis of
Alzheimer disease or cognitive impairment or depression (28–30)
were excluded because the effects of treatment in people with
established cognitive impairment may differ from those in the
general population. One trial in 299 Australian participants (31)
published after the specified cutoff for inclusion also reported no
significant effects of B vitamins on cognitive function, but in
a sensitivity analysis including the published results of this trial
with all other trials, the results for the effects of B vitamins on
cognitive aging were unaltered (Supplemental Table 6 under “Sup-
plemental data” in the online issue).
The doses of folic acid (0.4–2.5 mg) used in the individual
trials included in the present meta-analysis exceeded those re-
quired for maximal reduction in homocysteine concentrations.
The possibility that high doses of folic acid might cause harm
cannot be excluded, albeit there is no evidence of harm in pre-
vious trials (32). Except for one trial (10), all of the trials added
vitamin B-12 (0.4–1 mg), which produces further homocysteine
reduction and, with a daily dose ofw1 mg in 4 trials (7, 12, 14, 17),
should also correct for any undetected vitamin B-12 deficiency
(assuming that it is reversible) (33). On the basis of findings of
observational studies, it was anticipated that supplementation
with B vitamins might slow the rate of cognitive aging (2–5).
One-third of adults in the United States (34) and one-fifth of
adults in the United Kingdom (35) report taking daily multivi-
tamin supplements containing folic acid in the belief that they
have beneficial effects for health, including prevention of cog-
nitive aging. However, the claims that lowering homocysteine
can prevent cognitive aging (10, 36, 37) within just a few years
of treatment are not supported by the present meta-analysis. The
null results are not influenced by selective survival of partici-
pants to have cognitive testing at the end of the study period,
because supplementation with B vitamins had no effect on overall
mortality (22).
Although trials used combinations of B vitamins (vitamin
B-12 and vitamin B-6 in addition to folic acid) (22), it is unlikely
that this would obscure any effects of folic acid alone on cognitive
aging. Overall, homocysteine-lowering treatment with B vita-
mins did not substantially slow the rate of cognitive aging in older
people with or without vascular disease, irrespective of how
cognitive function was assessed. As with ischemic heart disease
(22, 38), the discrepant results of the observational studies and the
randomized trials for the effects of B vitamins on cognitive
function suggest that elevated plasma homocysteine is probably
a marker of underlying cognitive aging rather than a causal risk
factor (39).
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APPENDIX A
The following investigators were members of the B-Vitamin
Treatment Trialists’ Collaboration
Secretariat: Robert Clarke, Derrick Bennett, Sarah Parish,
Sarah Lewington, Jim Halsey, and Rory Collins (Clinical Trial Service
Unit) and Alan D Dangour (London School of Hygiene and Tropical
Medicine).
Cognitive-domain trials (ordered by number of participants):
McMahon: Murray Skeaff, Jennifer McMahon, Tim Green,
Jim Mann, Robert Knight, and Sheila Williams; Lewerin:
Catharina Lewerin and Herman Nilsson Ehle; Eussen: Simone
JPM Eussen, Lisette C de Groot, Wija A van Staveren, Willibrord
Hoefnagels, and Liesbeth W Joosten; Stott: David J Stott.
Global cognition trials—SEARCH: Jane Armitage and Rory
Collins; VITATOPS: Graeme J Hankey; WAFACS: JoAnn E
Manson, William Christen, and Francine Grodstein; VISP:
James Toole, M Rene Malinow, Lloyd Chambless, J David
Spence, Luther Pettigrew, Virginia Howard, Elizabeth Sides,
Chin-Hua Wang, and Meir Stampfer; SU.FOL.OM3: Pilar
Galan and Serge Hercberg; HOPE-2: Eva Lonn and Salim
Yusuf.
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